All Blogs
Oct 10, 2022
PCSK9 Inhibitors: A New Era for Cholesterol Management
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LD...
Read More...
Oct 07, 2022
Peripheral T-cell Lymphoma Treatment Market: How are Pipeline Therapies Reshaping the Therapeutic Outlook?
Peripheral T-cell Lymphoma (PTCL) is a diverse disorder category that accounts for 10% to 15% of non-Hodgkin lymphomas. Most PTCL subtypes, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal natural killer (NK) cell/T-cell lymphoma, are aggressive (fast-growing) lymphomas. PTCLs are...
Read More...
Oct 06, 2022
Olympus’s THUNDERBEAT Open Fine Jaw Type X Surgical Energy Device; Merit Medical’s TEMNO Elite; Thermo Fisher Scientific’s Oncomine Dx Target Test; Fujifilm Latest Generation Endoscopic Ultrasound; Indigo Diabetes’s Shine Clinical Trial; Cala Health Published Data for its TAPS Therapy
Olympus Launched THUNDERBEAT Open Fine Jaw Type X Surgical Energy Device On September 28, 2022, Olympus Corporation (Olympus), a global MedTech company, announced the release of the THUNDERBEAT™ Open Fine Jaw Type X surgical energy devices for open surgery. The device THUNDERBEAT Open Fine Jaw Type X surg...
Read More...
Oct 05, 2022
How is Vision Care Market Growing With the Ongoing Innovation in the Product Development?
The eyes are one of the most vital and critical body parts that provide aids in the processing of visual details. Being a very sensitive and delicate part, they require special care. Eyes defects can affect everyday activities and severely impact individuals and their families social and economic well-being. As per...
Read More...
Oct 04, 2022
Zealand Pharma’s Phase III Results of Glepaglutide; FDA Approves Amylyx’s ALS Drug Relyvrio; Novo Nordisk and Ventus Therapeutics Signs Licencing Deal; FDA Approves Futibatinib; Sarepta Files Duchenne Muscular Dystrophy for FDA Approval; Biogen and Eisai’s Lcanemab Phase III Study
Zealand Pharma Announces the Positive Topline Results from its Phase III trial of Glepaglutide Zealand Pharma A/S, a biotech company specializing in peptide-based medicines, announced positive topline results from its phase III trial of glepaglutide. In the evenly randomized double-blind trial, 106 patients with...
Read More...
Oct 03, 2022
Insights Into The Cutaneous T-cell Lymphoma Treatment Market
Cutaneous T-cell lymphomas (CTCLs) constitute a group of non-Hodgkin lymphomas of the skin. CTCL has an annual age-adjusted incidence of approximately 6 cases per million people. In the United States, approximately 1,000 new cases of skin lymphoma are diagnosed each year. CTCL affects males twice as females. Moreov...
Read More...
Oct 18, 2024
How are Antipsychotics Transforming the Schizophrenia Treatment Space?
Schizophrenia affects approximately 24 million people worldwide, or 1 in every 300 people (0.32%). In adults, this rate is 1 in 222 (0.45%). It is not as widespread as many other mental disorders. Onset occurs most frequently in late adolescence and the twenties, and it occurs earlier in men than in women. Schiz...
Read More...
Sep 29, 2022
Asahi Intecc Partners with Penumbra; Prosoma and EVERSANA Announce Commercialisation Partnership; Zynex Starts Enrollment in the Blood Loss Detection Clinical Trial; Reva Initiates Enrollment in the MOTIV IDE Clinical Trial; FDA Clearance to QT Imaging to Calculate Fibroglandular Volume of the Breast; FDA 510k Clearance to iMediSync’s EEG scanner ‘iSyncWave’
Asahi Intecc partners with Penumbra to roll out Indigo System in Japan On September 22, 2022, Asahi Intecc, a Surgical and medical instrument manufacturing company, partnered with Penumbra, a medical device company headquartered in Alameda, California, to roll out Indigo System in Japan. After getting regulat...
Read More...
Sep 28, 2022
Evaluating the Growing Role of Devices in the Rehabilitation of Hearing Impairment
Hearing loss is a growing public health concern, and the number of cases is rising globally at a significant pace. As per the WHO, more than 1.5 billion people (nearly 20% of the global population) live with hearing loss, and 430 million of them have disabling hearing loss. According to the NIDCD, in the United Sta...
Read More...
Sep 27, 2022
Daiichi Sankyo’s Ezharmia; Pfizer & Sangamo Hemophilia A Gene Therapy Trial; Approval for Fennec’s Pedmark; FDA Approves UBE and Santen’s OMLONTI; EC Approves AstraZeneca’s Tezspire; FDA Approves Selpercatinib; FDA Grants Accelerated Approval to Eli Lilly’s Retevmo; GSK & Spero Announce Exclusive License Agreement
Daiichi Sankyo Receives the First Approval for its Blood Cancer Drug Ezharmia Daiichi Sankyo has received the first global approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL). The Japanese Ministry of ...
Read More...